FindTrial
Sign In

PREDICTIVE PERFORMANCE OF ''TARGET CONTROLLED INFUSION'' OF PROPOFOL ASSOCIATED WITH NEUROPHISIOLOGIC MONITORING WITH BISPECTRAL INDEX AND CEREBRAL STATE INDEX IN PATIENT WITH ELEVATED ANESTESIOLOGIC RISK.

PREDICTIVE PERFORMANCE OF ''TARGET CONTROLLED INFUSION'' OF PROPOFOL ASSOCIATED WITH NEUROPHISIOLOGIC MONITORING WITH BISPECTRAL INDEX AND CEREBRAL STATE INDEX IN PATIENT WITH ELEVATED ANESTESIOLOGIC RISK.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-002527-14-IT
Enrollment
35
Registered
2007-10-03
Start date
2005-07-01
Completion date
Unknown
Last updated
2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANAESTESIOLGY IN ASA III MedDRA version: 6.1 Level: SOC Classification code 10017947

Interventions

Trade Name: DIPRIVAN*INFUS 50ML 20MG/ML Pharmaceutical Form: Solution for infusion INN or Proposed INN: Propofol CAS Number: 2078-54-8 Concentration unit: mg milligram(s) Concentration type: equal Con

Sponsors

OSPEDALE S. RAFFAELE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026